Catheter Precision, Inc. VTAK

Company Overview

Catheter Precision, Inc. (NYSE American: VTAK) is a U.S.-based medical technology company focused on cardiac electrophysiology products used in the diagnosis and treatment of cardiac arrhythmias. The company operates within the broader cardiovascular medical device and electrophysiology industries, developing technologies intended to improve catheter navigation, arrhythmia mapping, and procedural efficiency during minimally invasive cardiac procedures. Its primary commercial focus has centered on advanced cardiac mapping and navigation systems designed for electrophysiologists treating conditions such as atrial fibrillation and other irregular heart rhythms.

The company’s principal revenue drivers include its electrophysiology technologies and related disposable or procedural products. Key products historically associated with the company include the VIVO (View Into Ventricular Onset) non-invasive cardiac mapping system and the LockeT vascular closure device. Catheter Precision evolved through acquisitions and restructuring activities involving earlier electrophysiology-focused businesses, including technology assets connected to cardiac mapping and procedural guidance. The company positions itself as a smaller specialized innovator competing in segments traditionally dominated by larger cardiovascular device manufacturers by emphasizing workflow enhancement, non-invasive mapping capabilities, and physician-focused procedural tools.